News | April 29, 2025
Pfizer Q1 2025 revenue drops 8% to $13.7 billion
Delivers robust earnings performance, successfully navigating a dynamic environment
Delivers robust earnings performance, successfully navigating a dynamic environment
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Rising demands and advancements in eye care drive growth
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Awards highlight Avantor's commitment to the Biopharma industry
FlexiTubes will showcase range of eco-friendly and innovative tube options
Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score
Subscribe To Our Newsletter & Stay Updated
